217 related articles for article (PubMed ID: 26291379)
1. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.
Hariri S; Markowitz LE; Bennett NM; Niccolai LM; Schafer S; Bloch K; Park IU; Scahill MW; Julian P; Abdullah N; Levine D; Whitney E; Unger ER; Steinau M; Bauer HM; Meek J; Hadler J; Sosa L; Powell SE; Johnson ML;
Emerg Infect Dis; 2015 Sep; 21(9):1557-61. PubMed ID: 26291379
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
4. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
[TBL] [Abstract][Full Text] [Related]
5. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.
Benard VB; Castle PE; Jenison SA; Hunt WC; Kim JJ; Cuzick J; Lee JH; Du R; Robertson M; Norville S; Wheeler CM;
JAMA Oncol; 2017 Jun; 3(6):833-837. PubMed ID: 27685805
[TBL] [Abstract][Full Text] [Related]
6. Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions.
Russ SM; Brackney M; Meek J; Niccolai LM
Vaccine; 2019 Jul; 37(31):4262-4267. PubMed ID: 31248688
[TBL] [Abstract][Full Text] [Related]
7. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States.
Hariri S; Johnson ML; Bennett NM; Bauer HM; Park IU; Schafer S; Niccolai LM; Unger ER; Markowitz LE;
Cancer; 2015 Aug; 121(16):2775-81. PubMed ID: 26098295
[TBL] [Abstract][Full Text] [Related]
8. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
10. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of nonavalent HPV vaccine in the prevention of high-grade cervical lesions and cervical cancer in Portugal.
Pista A; de Oliveira CF; Lopes C; Cunha MJ;
Int J Gynaecol Obstet; 2017 Oct; 139(1):90-94. PubMed ID: 28632949
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
13. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
14. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
[TBL] [Abstract][Full Text] [Related]
16. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
17. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
[TBL] [Abstract][Full Text] [Related]
18. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
Pérez-Castro S; Lorenzo-Mahía Y; Iñarrea Fernández A; Lamas-González MJ; Sarán-Díez MT; Rubio-Alarcón J; Reboredo-Reboredo MC; Mosteiro-Lobato S; López-Miragaya I; Torres-Piñón J; Melón-García S
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):479-85. PubMed ID: 24274937
[TBL] [Abstract][Full Text] [Related]
19. Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.
Xu XX; Zhou JS; Yuan SH; Yu H; Lou HM
Int J Environ Res Public Health; 2015 Sep; 12(9):10794-805. PubMed ID: 26404339
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18.
Johnson Jones ML; Gargano JW; Powell M; Park IU; Niccolai LM; Bennett NM; Griffin MR; Querec T; Unger ER; Markowitz LE;
Am J Epidemiol; 2020 Apr; 189(4):265-276. PubMed ID: 31680146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]